Brussels, 25/03/2008 (Agence Europe) - On Thursday 20 March, the Belgian pharmaceutical group, UCB, announced that its anti-Parkinson's disease drug, Neupro, would be withdrawn from the USA, as well as certain batches of the drug in Europe. A company press release explained that the batches in question did not satisfy specifications approved by the regulatory authorities. It also added that this decision did not mean that any contamination or product toxicity was involved but rather, a...